Study guide

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal

Key Takeaways Explain This Topic AI

Unfractionated heparin binds antithrombin and inhibits thrombin and factor Xa equally; it is monitored by the aPTT or ACT and fully reversed by protamine 1 mg per 100 units of heparin given in the previous 2-3 hours.

Low molecular weight heparins mainly inhibit factor Xa, are renally cleared, are monitored by anti-Xa activity, and are only partly (about 60%) reversed by protamine.

Warfarin is reversed urgently with four-factor prothrombin complex concentrate (about 25-50 units/kg depending on INR) plus intravenous vitamin K 5-10 mg.

Idarucizumab 5 g reverses dabigatran, and andexanet alfa or four-factor prothrombin complex concentrate is used for life-threatening bleeding on apixaban or rivaroxaban.

Aspirin irreversibly inhibits platelet cyclo-oxygenase-1, and clopidogrel, prasugrel and ticagrelor block the P2Y12 receptor; platelet transfusion is the main option for urgent reversal, but it is less effective while ticagrelor is still circulating.

Last updated: October 2026

  • 10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal
  • Why This Topic Matters

Anticoagulant and antiplatelet drugs affect timing of surgery, choice of neuraxial or regional techniques, transfusion strategy and the management of bleeding. EDAIC questions test mechanisms, pharmacokinetics, laboratory monitoring and reversal.

  • Heparins
  • Unfractionated Heparin (UFH)

Mechanism: A mixture of sulphated glycosaminoglycans (mean molecular weight about 15 kDa). A specific pentasaccharide sequence binds antithrombin and accelerates its action about 1,000-fold. Chains longer than 18 saccharides can bridge antithrombin and thrombin, so UFH inhibits thrombin (IIa) and factor Xa equally .

Pharmacokinetics: Binds plasma proteins, endothelium and macrophages, so the dose-response is unpredictable. Half-life is about 1-2 hours, increasing with dose. Clearance is mainly by the reticuloendothelial system, so it is suitable in renal failure.

Monitoring: aPTT (therapeutic ratio about 1.5-2.5) or activated clotting time (ACT) during cardiopulmonary bypass (target above about 400-480 seconds).

Reversal: Protamine sulphate , a basic protein that forms a stable salt with heparin; 1 mg neutralises about 100 units of heparin. Give slowly to avoid hypotension; severe reactions include catastrophic pulmonary vasoconstriction.

Adverse effects: Heparin-induced thrombocytopenia (HIT), osteoporosis with long-term use, hyperkalaemia through aldosterone suppression, and heparin resistance from antithrombin deficiency.

Low Molecular Weight Heparin (LMWH)

Shorter chains (mean about 4-5 kDa) cannot bridge thrombin, so activity is mainly anti-Xa (anti-Xa:anti-IIa ratio about 2-4:1 for enoxaparin).

Predictable subcutaneous absorption, half-life about 4-6 hours, renal excretion : reduce the dose when creatinine clearance is below 30 mL/min.

Monitored by anti-Xa activity (for example in renal failure, pregnancy or obesity).

Protamine reverses only about 60% of the anti-Xa activity.

Lower risk of HIT than UFH.

Fondaparinux

A synthetic pentasaccharide that binds antithrombin and inhibits only factor Xa. Half-life about 17-21 hours, renally excreted, not reversed by protamine, and does not cross-react with HIT antibodies.

Vitamin K Antagonists

Warfarin inhibits vitamin K epoxide reductase (VKORC1) , preventing regeneration of reduced vitamin K needed for gamma-carboxylation of factors II, VII, IX and X and proteins C and S.

Highly protein-bound (about 99%), metabolised by CYP2C9 ; genetic variants of CYP2C9 and VKORC1 alter dose requirements.

Many interactions: enzyme inhibitors (amiodarone, metronidazole, fluconazole) raise the INR; enzyme inducers (rifampicin, carbamazepine) lower it.

Elective surgery: stop about 5 days before; bridge with LMWH only in high thrombotic risk (for example mechanical mitral valve).

Emergency reversal: four-factor prothrombin complex concentrate (PCC) (about 25-50 units/kg depending on INR and product) plus vitamin K 5-10 mg intravenously . Vitamin K takes 6-12 hours to act; fresh frozen plasma is a slower, larger-volume alternative.

Direct Oral Anticoagulants (DOACs)

  • Drug Target Renal excretion Half-life (normal renal function) Specific reversal
  • Dabigatran Thrombin About 80% 12-17 h Idarucizumab 5 g IV; also dialysable

Rivaroxaban Factor Xa About 33% unchanged (about two-thirds eliminated renally overall) 5-13 h Andexanet alfa, or four-factor PCC

  • Apixaban Factor Xa About 27% About 12 h Andexanet alfa, or four-factor PCC
  • Edoxaban Factor Xa About 50% 10-14 h Four-factor PCC (andexanet not licensed for edoxaban)

Routine tests are unreliable: dabigatran prolongs the thrombin time (a normal thrombin time excludes significant levels); anti-Xa assays calibrated for the specific drug measure factor Xa inhibitors.

Elective interruption depends on bleeding risk and renal function: for factor Xa inhibitors, usually at least 24 hours for low-risk and 48 hours for high-risk surgery; dabigatran needs longer intervals when creatinine clearance falls (see the preoperative assessment section).

Andexanet alfa is a modified recombinant factor Xa decoy that binds factor Xa inhibitors. It also binds heparin-antithrombin complexes, which can cause heparin resistance if cardiopulmonary bypass is needed.

Antiplatelet Drugs

Drug Mechanism Reversibility Usual stop before surgery (if stopping is needed)

Aspirin Irreversible acetylation of COX-1, blocking thromboxane A2 Irreversible (platelet lifespan 7-10 days) Usually continued; stop about 7 days before for very high bleeding-risk sites

  • Clopidogrel Prodrug; active metabolite irreversibly blocks P2Y12 Irreversible 5 days
  • Prasugrel Prodrug; irreversible P2Y12 block, more potent Irreversible 7 days
  • Ticagrelor Direct, reversible P2Y12 antagonist Reversible 3-5 days

Glycoprotein IIb/IIIa inhibitors (tirofiban, eptifibatide, abciximab) Block fibrinogen binding Short-acting except abciximab Hours

Dipyridamole Phosphodiesterase inhibition and adenosine reuptake blockade Reversible 24-48 hours

Clopidogrel needs activation by CYP2C19 ; poor metabolisers and patients taking inhibitors (such as omeprazole) have a reduced effect.

After coronary stenting, dual antiplatelet therapy should not be interrupted without cardiology advice; elective surgery is usually deferred until the minimum duration has been completed.

Reversal: platelet transfusion restores function for irreversible inhibitors once the drug has been cleared from plasma; with ticagrelor the active drug inhibits transfused platelets, so transfusion is less effective in the first day after the last dose. Desmopressin may improve platelet function in some cases.

Thrombolytics

Alteplase , tenecteplase and reteplase convert plasminogen to plasmin. They are used for acute ischaemic stroke (alteplase 0.9 mg/kg, maximum 90 mg, within 4.5 hours of onset), massive pulmonary embolism and, less often now, myocardial infarction. Recent major surgery is a contraindication. Life-threatening bleeding after thrombolysis is treated with cryoprecipitate or fibrinogen and tranexamic acid.

Haemostatic Drugs

Drug Mechanism Uses

Tranexamic acid Lysine analogue preventing plasminogen binding to fibrin Trauma (within 3 hours), postpartum haemorrhage, cardiac and orthopaedic surgery; reduce dose in renal failure; high doses can cause seizures

Prothrombin complex concentrate Factors II, VII, IX, X (four-factor) with proteins C and S Warfarin reversal; factor Xa inhibitor bleeding when andexanet is unavailable

Fibrinogen concentrate / cryoprecipitate Replace fibrinogen Hypofibrinogenaemia in massive haemorrhage

Recombinant factor VIIa Drives thrombin generation on activated platelets Haemophilia with inhibitors; not recommended routinely in trauma because of arterial thrombosis risk

Protamine Neutralises heparin Reversal of UFH; partial for LMWH